CellSeed

CellSeed Equity Turnover

The Equity Turnover of CellSeed (7776.T) as of Oct 27, 2026 is 0.07. In the previous year, Equity Turnover was 0.09 — a change of -26.16% (lower).

Equity Turnover

0.07

YoY

-26.16%

Last updated:

Equity Turnover of CellSeed is 2025 0.07 . Equity Turnover of CellSeed was 2024 0.09 . It decreases by -26.16% lower compared to the previous year.

The CellSeed Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
0.73 JPY
Jan 1, 2019
0.20 JPY
Jan 1, 2020
0.13 JPY
Jan 1, 2021
0.15 JPY
Jan 1, 2022
0.11 JPY
Jan 1, 2023
0.09 JPY
Jan 1, 2024
0.09 JPY
Jan 1, 2025
0.07 JPY
The CellSeed Equity Turnover history
YEAREquity TurnoverYoY
0.07-26.16%
0.09+1.72%
0.09-18.14%
0.11-30.67%
0.15+18.43%
0.13-36.24%
0.20-71.80%
0.73+975.39%
0.07-21.83%
0.09+7.05%
0.08+164.59%
0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Equity Turnover of CellSeed is 0.07 in 2025.

Equity Turnover of CellSeed changed from 0.09 to 0.07, representing a -26.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover CellSeed since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's CellSeed with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CellSeed

All Key Metrics — CellSeed